Wall Street Zen Downgrades Sage Therapeutics (NASDAQ:SAGE) to Sell

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

A number of other equities analysts have also recently weighed in on the company. HC Wainwright reissued a "neutral" rating and issued a $12.00 price target (down previously from $14.00) on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Bank of America assumed coverage on Sage Therapeutics in a research note on Tuesday, March 11th. They set an "underperform" rating and a $5.00 target price on the stock. Canaccord Genuity Group lowered their target price on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a research note on Wednesday, February 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of Sage Therapeutics in a research note on Friday, April 25th. Finally, Scotiabank lowered their target price on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $8.87.

Sage Therapeutics Trading Up 1.0%

Shares of SAGE opened at $6.85 on Friday. The business's 50-day moving average price is $6.99 and its 200 day moving average price is $6.80. The stock has a market capitalization of $428.95 million, a P/E ratio of -1.04 and a beta of 0.20. Sage Therapeutics has a 1-year low of $4.62 and a 1-year high of $13.47.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). The company had revenue of $14.06 million during the quarter, compared to analysts' expectations of $14.12 million. Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The company's revenue for the quarter was up 78.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.80) EPS. On average, research analysts predict that Sage Therapeutics will post -3.52 earnings per share for the current year.

Institutional Investors Weigh In On Sage Therapeutics

Several institutional investors have recently made changes to their positions in SAGE. SG Americas Securities LLC lifted its holdings in shares of Sage Therapeutics by 57.7% during the 4th quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company's stock valued at $122,000 after buying an additional 8,228 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Sage Therapeutics during the 4th quarter valued at about $91,000. Ieq Capital LLC acquired a new stake in Sage Therapeutics in the 4th quarter worth approximately $57,000. US Bancorp DE lifted its holdings in Sage Therapeutics by 22.3% in the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock worth $67,000 after purchasing an additional 2,268 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Sage Therapeutics by 2.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 462,309 shares of the biopharmaceutical company's stock worth $2,510,000 after purchasing an additional 10,116 shares during the last quarter. 99.22% of the stock is currently owned by institutional investors and hedge funds.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.